Results 221 to 230 of about 1,085,785 (298)

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Management of dyslipidaemia in patients with comorbidities-facing the challenge: type 1 diabetes mellitus. [PDF]

Eur Heart J Cardiovasc Pharmacother
Kaser S, Dobrev D, Rocca B, Kaski JC, Agewall S, Drexel H.   +5 more
europepmc   +1 more source

The association between PAI-1 -675 4G/5G polymorphism and type 2 diabetes mellitus

, 2017
Lie Chen, Siying Li, Mao Liu
openalex   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Linking epigenetic mechanisms of T cell dysfunction with pathophysiology of type 1 diabetes mellitus. [PDF]

Front Immunol
Jabri A, Elsalti A, Alsharif M, Alsharif R, Abbad T, Sibai D, Taftafa B, Mhannayeh A, Khan MI, Yaqinuddin A.   +9 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Satisfaction with life in young adults with type 1 diabetes mellitus. [PDF]

Sci Rep
Stefanowicz-Bielska A, Rąpała M, Mazuryk K, Kawa M, Dygaszewicz E.   +4 more
europepmc   +1 more source

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert, Jenny Dimakos, Ying Cui, Kristian B. Filion, Christel Renoux, Antonios Douros   +5 more
wiley   +1 more source